ATC code L01
| ATC codes |
|---|
| L Antineoplastic and immunomodulating agents |
| L01 Antineoplastic agents |
| L02 Endocrine therapy |
| L03 Immunostimulants |
| L04 Immunosuppressants |
|
|
ATC code L01 Antineoplastic agents is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products.[1][2][3] Subgroup L01 is part of the anatomical group L Antineoplastic and immunomodulating agents.[4]
Codes for veterinary use (ATCvet codes) can be created by placing the letter Q in front of the human ATC code: for example, QL01.[5] ATCvet codes without corresponding human ATC codes are cited with the leading Q in the following list.
National issues of the ATC classification may include additional codes not present in this list, which follows the WHO version.
L01A Alkylating agents
L01AA Nitrogen mustard analogues
- L01AA01 Cyclophosphamide
- L01AA02 Chlorambucil
- L01AA03 Melphalan
- L01AA05 Chlormethine
- L01AA06 Ifosfamide
- L01AA07 Trofosfamide
- L01AA08 Prednimustine
- L01AA09 Bendamustine
- L01AA10 Melphalan flufenamide
L01AB Alkyl sulfonates
- L01AB01 Busulfan
- L01AB02 Treosulfan
- L01AB03 Mannosulfan
L01AC Ethylene imines
- L01AC01 Thiotepa
- L01AC02 Triaziquone
- L01AC03 Carboquone
L01AD Nitrosoureas
- L01AD01 Carmustine
- L01AD02 Lomustine
- L01AD03 Semustine
- L01AD04 Streptozocin
- L01AD05 Fotemustine
- L01AD06 Nimustine
- L01AD07 Ranimustine
- L01AD08 Uramustine
L01AG Epoxides
- L01AG01 Etoglucid
L01AX Other alkylating agents
- L01AX01 Mitobronitol
- L01AX02 Pipobroman
- L01AX03 Temozolomide
- L01AX04 Dacarbazine
L01B Antimetabolites
L01BA Folic acid analogues
- L01BA01 Methotrexate
- L01BA03 Raltitrexed
- L01BA04 Pemetrexed
- L01BA05 Pralatrexate
L01BB Purine analogues
- L01BB02 Mercaptopurine
- L01BB03 Tioguanine
- L01BB04 Cladribine
- L01BB05 Fludarabine
- L01BB06 Clofarabine
- L01BB07 Nelarabine
- QL01BB90 Rabacfosadine
L01BC Pyrimidine analogues
- L01BC01 Cytarabine
- L01BC02 Fluorouracil
- L01BC03 Tegafur
- L01BC04 Carmofur
- L01BC05 Gemcitabine
- L01BC06 Capecitabine
- L01BC07 Azacitidine
- L01BC08 Decitabine
- L01BC09 Floxuridine
- L01BC52 Fluorouracil, combinations
- L01BC53 Tegafur, combinations
- L01BC59 Trifluridine, combinations
L01C Plant alkaloids and other natural products
L01CA Vinca alkaloids and analogues
- L01CA01 Vinblastine
- L01CA02 Vincristine
- L01CA03 Vindesine
- L01CA04 Vinorelbine
- L01CA05 Vinflunine
- L01CA06 Vintafolide
L01CB Podophyllotoxin derivatives
- L01CB01 Etoposide
- L01CB02 Teniposide
L01CC Colchicine derivatives
- L01CC01 Demecolcine
L01CD Taxanes
- L01CD01 Paclitaxel
- L01CD02 Docetaxel
- L01CD03 Paclitaxel poliglumex
- L01CD04 Cabazitaxel
L01CE Topoisomerase 1 (TOP1) inhibitors
- L01CE01 Topotecan
- L01CE02 Irinotecan
- L01CE03 Etirinotecan pegol
- L01CE04 Belotecan
L01CX Other plant alkaloids and natural products
- L01CX01 Trabectedin
L01D Cytotoxic antibiotics and related substances
L01DA Actinomycines
- L01DA01 Dactinomycin
L01DB Anthracyclines and related substances
- L01DB01 Doxorubicin
- L01DB02 Daunorubicin
- L01DB03 Epirubicin
- L01DB04 Aclarubicin
- L01DB05 Zorubicin
- L01DB06 Idarubicin
- L01DB07 Mitoxantrone
- L01DB08 Pirarubicin
- L01DB09 Valrubicin
- L01DB10 Amrubicin
- L01DB11 Pixantrone
L01DC Other cytotoxic antibiotics
- L01DC01 Bleomycin
- L01DC02 Plicamycin
- L01DC03 Mitomycin
- L01DC04 Ixabepilone
L01E Protein kinase inhibitors
L01EA BCR-ABL tyrosine kinase inhibitors
L01EB Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
- L01EB01 Gefitinib
- L01EB02 Erlotinib
- L01EB03 Afatinib
- L01EB04 Osimertinib
- L01EB05 Rociletinib
- L01EB06 Olmutinib
- L01EB07 Dacomitinib
- L01EB08 Icotinib
L01EC B-Raf serine-threonine kinase (BRAF) inhibitors
- L01EC01 Vemurafenib
- L01EC02 Dabrafenib
- L01EC03 Encorafenib
L01ED Anaplastic lymphoma kinase (ALK) inhibitors
- L01ED01 Crizotinib
- L01ED02 Ceritinib
- L01ED03 Alectinib
- L01ED04 Brigatinib
- L01ED05 Lorlatinib
L01EE Mitogen-activated protein kinase (MEK) inhibitors
- L01EE01 Trametinib
- L01EE02 Cobimetinib
- L01EE03 Binimetinib
- L01EE04 Selumetinib
L01EF Cyclin-dependent kinase (CDK) inhibitors
- L01EF01 Palbociclib
- L01EF02 Ribociclib
- L01EF03 Abemaciclib
L01EG Mammalian target of rapamycin (mTOR) kinase inhibitors
- L01EG01 Temsirolimus
- L01EG02 Everolimus
- L01EG03 Ridaforolimus
L01EH Human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitors
L01EJ Janus-associated kinase (JAK) inhibitors
- L01EJ01 Ruxolitinib
- L01EJ02 Fedratinib
- L01EJ03 Pacritinib
L01EK Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors
L01EL Bruton's tyrosine kinase (BTK) inhibitors
- L01EL01 Ibrutinib
- L01EL02 Acalabrutinib
- L01EL03 Zanubrutinib
L01EM Phosphatidylinositol-3-kinase (Pi3K) inhibitors
- L01EM01 Idelalisib
- L01EM02 Copanlisib
- L01EM03 Alpelisib
- L01EM04 Duvelisib
L01EN Fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors
- L01EN01 Erdafitinib
- L01EN02 Pemigatinib
- L01EN03 Infigratinib
- L01EN04 Futibatinib
L01EX Other protein kinase inhibitors
- L01EX01 Sunitinib
- L01EX02 Sorafenib
- L01EX03 Pazopanib
- L01EX04 Vandetanib
- L01EX05 Regorafenib
- L01EX06 Masitinib
- L01EX07 Cabozantinib
- L01EX08 Lenvatinib
- L01EX09 Nintedanib
- L01EX10 Midostaurin
- L01EX11 Quizartinib
- L01EX12 Larotrectinib
- L01EX13 Gilteritinib
- L01EX14 Entrectinib
- L01EX15 Pexidartinib
- L01EX17 Capmatinib
- L01EX18 Avapritinib
- L01EX19 Ripretinib
- L01EX21 Tepotinib
- L01EX22 Selpercatinib
- L01EX23 Pralsetinib
- QL01EX90 Toceranib
L01F Monoclonal antibodies and antibody drug conjugates
L01FA CD20 (Clusters of Differentiation 20) inhibitors
- L01FA01 Rituximab
- L01FA02 Ofatumumab
- L01FA03 Obinutuzumab
L01FB CD22 (Clusters of Differentiation 22) inhibitors
- L01FB01 Inotuzumab ozogamicin
- L01FB02 Moxetumomab pasudotox
L01FC CD38 (Clusters of Differentiation 38) inhibitors
- L01FC01 Daratumumab
- L01FC02 Isatuximab
L01FD HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors
- L01FD01 Trastuzumab
- L01FD02 Pertuzumab
- L01FD03 Trastuzumab emtansine
- L01FD04 Trastuzumab deruxtecan
- L01FD05 Trastuzumab duocarmazine
L01FE EGFR (Epidermal Growth Factor Receptor) inhibitors
- L01FE01 Cetuximab
- L01FE02 Panitumumab
- L01FE03 Necitumumab
L01FF PD-1/PDL-1 (Programmed cell death protein 1/ death ligand 1) inhibitors
- L01FF01 Nivolumab
- L01FF02 Pembrolizumab
- L01FF03 Durvalumab
- L01FF04 Avelumab
- L01FF05 Atezolizumab
- L01FF06 Cemiplimab
- L01FF07 Dostarlimab
- L01FF08 Prolgolimab
- L01FF09 Tislelizumab
- L01FF10 Retifanlimab
L01FG VEGF/VEGFR (Vascular Endothelial Growth Factor) inhibitors
- L01FG01 Bevacizumab
- L01FG02 Ramucirumab
L01FX Other monoclonal antibodies and antibody drug conjugates
- L01FX01 Edrecolomab
- L01FX02 Gemtuzumab ozogamicin
- L01FX03 Catumaxomab
- L01FX04 Ipilimumab
- L01FX05 Brentuximab vedotin
- L01FX06 Dinutuximab beta
- L01FX07 Blinatumomab
- L01FX08 Elotuzumab
- L01FX09 Mogamulizumab
- L01FX10 Olaratumab
- L01FX11 Bermekimab
- L01FX12 Tafasitamab
- L01FX13 Enfortumab vedotin
- L01FX14 Polatuzumab vedotin
- L01FX15 Belantamab mafodotin
- L01FX16 Oportuzumab monatox
- L01FX17 Sacituzumab govitecan
- L01FX18 Amivantamab
L01X Other antineoplastic agents
L01XA Platinum compounds
- L01XA01 Cisplatin
- L01XA02 Carboplatin
- L01XA03 Oxaliplatin
- L01XA04 Satraplatin
- L01XA05 Polyplatillen
L01XB Methylhydrazines
- L01XB01 Procarbazine
L01XD Sensitizers used in photodynamic/radiation therapy
- L01XD01 Porfimer sodium
- L01XD03 Methyl aminolevulinate
- L01XD04 Aminolevulinic acid
- L01XD05 Temoporfin
- L01XD06 Efaproxiral
- L01XD07 Padeliporfin
L01XF Retinoids for cancer treatment
- L01XF01 Tretinoin
- L01XF02 Alitretinoin
- L01XF03 Bexarotene
L01XG Proteasome inhibitors
- L01XG01 Bortezomib
- L01XG02 Carfilzomib
- L01XG03 Ixazomib
L01XH Histone deacetylase (HDAC) inhibitors
- L01XH01 Vorinostat
- L01XH02 Romidepsin
- L01XH03 Panobinostat
- L01XH04 Belinostat
- L01XH05 Entinostat
L01XJ Hedgehog pathway inhibitors
- L01XJ01 Vismodegib
- L01XJ02 Sonidegib
- L01XJ03 Glasdegib
L01XK Poly (ADP-ribose) polymerase (PARP) inhibitors
L01XX Other antineoplastic agents
- L01XX01 Amsacrine
- L01XX02 Asparaginase
- L01XX03 Altretamine
- L01XX05 Hydroxycarbamide
- L01XX07 Lonidamine
- L01XX08 Pentostatin
- L01XX10 Masoprocol
- L01XX11 Estramustine
- L01XX16 Mitoguazone
- L01XX18 Tiazofurine
- L01XX23 Mitotane
- L01XX24 Pegaspargase
- L01XX27 Arsenic trioxide
- L01XX29 Denileukin diftitox
- L01XX33 Celecoxib
- L01XX35 Anagrelide
- L01XX36 Oblimersen
- L01XX37 Sitimagene ceradenovec
- L01XX40 Omacetaxine mepesuccinate
- L01XX41 Eribulin
- L01XX44 Aflibercept
- L01XX46 Olaparib
- L01XX51 Talimogene laherparepvec
- L01XX52 Venetoclax
- L01XX53 Vosaroxin
- L01XX57 Plitidepsin
- L01XX58 Epacadostat
- L01XX59 Enasidenib
- L01XX62 Ivosidenib
- L01XX66 Selinexor
- L01XX67 Tagraxofusp
- L01XX69 Lurbinectedin
- L01XX70 Axicabtagene ciloleucel
- L01XX71 Tisagenlecleucel
- L01XX72 Tazemetostat
- L01XX73 Sotorasib
- L01XX74 Belzutifan
- QL01XX91 Tigilanol tiglate
- QL01XX92 Verdinexor
L01XY Combinations of antineoplastic agents
- L01XY01 Cytarabine and daunorubicin
- L01XY02 Pertuzumab and trastuzumab
References
- ↑ "ATC (Anatomical Therapeutic Chemical Classification System) – Synopsis". National Institutes of Health. Retrieved 1 February 2020.
- ↑ World Health Organization. "Anatomical Therapeutic Chemical (ATC) Classification". World Health Organization. Retrieved 3 January 2022.
- ↑ "Structure and principles". WHO Collaborating Centre for Drug Statistics Methodology. 15 February 2018. Retrieved 3 January 2022.
- ↑ "ATC/DDD Index 2022: code L01". WHO Collaborating Centre for Drug Statistics Methodology.
- ↑ "ATCvet Index 2022: code QL01". WHO Collaborating Centre for Drug Statistics Methodology.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.